By Val Brickates Kennedy 2%0%-2%-4%10a11a12p1p2p3pFACT ITMN ABT BTK DRG BOSTON (MarketWatch) -- Facet Biotech Corp. /quotes/comstock/15*!fact/quotes/nls/fact (FACT 26.94, +10.73, +66.19%) and InterMune Inc. /quotes/comstock/15*!itmn/quotes/nls/itmn (ITMN 38.99, +15.69, +67.34%) were the lead advancers among biotech stocks Wednesday, with both stocks rocketing over 60% in early trading. Facet shares shot up to $26.95, the morning after Abbott Laboratories /quotes/comstock/13*!abt/quotes/nls/abt (ABT 54.97, +0.17, +0.32%) said it plans to buy the drug developer for $27 a share in cash. InterMune shares, meanwhile, soared to $38.11 on news that an advisory panel of the U.S. Food And Drug Administration had voted Tuesday to recommend that agency approve its new pulmonary drug. The NYSE Arca Biotechnology Index /quotes/comstock/10t!btk.x (BTK 1,232, +64.73, +5.55%) jumped 4.6% to 1221.35, pushed higher by component InterMune. The NYSE Arca Pharmaceutical Index /quotes/comstock/10t!drg.x (DRG 306.34, +0.19, +0.06%) was largely flat at 306.00.